Deal Watch: Allergan Buys Kythera Anticipating Kybella Will Bolster Its Aesthetic Portfolio
Johnson & Johnson Innovation announces a spate of 17 deals, bringing its two-year total to more than 200 agreements. Celgene pays $82.5 million up front to partner with Kythera on a ROR gamma T program for cancer immunotherapy.
You may also be interested in...
In an effort to expand outreach to and interaction with innovation-rich communities, J&J is creating four new regional innovation centers to act as scouts, deal-makers and alliance managers in Shanghai, Boston, California and London.
The US FDA approved the first antibody cocktail for ebolavirus infection, supporting a supply contract with BARDA. The development experience informed Regeneron's work in COVID-19.
The long-acting neuromodulator improved symptoms of cervical dystonia in a Phase III trial with longer duration of efficacy versus older products; a launch for aesthetics is expected soon.